Bivalirudin vs Orforglipron
Overview
Bivalirudin is primarily a cardiovascular peptide, while Orforglipron is used for weight management & metabolic.
This page compares Bivalirudin and Orforglipron across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Bivalirudin | Orforglipron | |
|---|---|---|
| Category | Cardiovascular | Weight Management & Metabolic |
| Regulatory status (US) | FDA approved | FDA approved |
| Typical dosage | 0.75 mg/kg IV bolus, then 1.75 mg/kg/h IV infusion | Clinical trials |
| Frequency | Single procedural session: bolus immediately before PCI followed by continuous infusion during the procedure; optional post-procedural infusion for up to approximately 20 hours | daily |
| Reported benefits | Anticoagulation during PCI and PTCA, anticoagulation in HIT/HITTS patients undergoing PCI, reduced major bleeding versus heparin plus glycoprotein IIb/IIIa inhibitor, predictable pharmacokinetics without need for antithrombin cofactor, rapid offset of anticoagulation due to short half-life, inhibition of both circulating and clot-bound thrombin | Oral administration convenience, weight loss, glucose control |
| Reported side effects | Bleeding (most common, including access-site and retroperitoneal), acute stent thrombosis (early, within 24 hours), back pain, nausea, headache, hypotension, injection-site pain, hypersensitivity reactions, thrombocytopenia (rare) | Under investigation |
Key differences
Primary use. Bivalirudin is categorised under Cardiovascular, while Orforglipron falls under Weight Management & Metabolic. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. Bivalirudin: FDA-approved. Orforglipron: FDA-approved.
Dosing. Bivalirudin is typically dosed at 0.75 mg/kg IV bolus, then 1.75 mg/kg/h IV infusion (Single procedural session: bolus immediately before PCI followed by continuous infusion during the procedure; optional post-procedural infusion for up to approximately 20 hours). Orforglipron is typically dosed at Clinical trials (daily).
Can you stack them?
Some protocols combine peptides, but stacking Bivalirudin and Orforglipron has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Bivalirudin and Orforglipron?
- Bivalirudin is primarily a cardiovascular peptide, while Orforglipron is used for weight management & metabolic. Bivalirudin is FDA-approved for one or more indications, whereas Orforglipron is FDA-approved for one or more indications.
- What is Bivalirudin used for?
- FDA-approved synthetic peptide direct thrombin inhibitor used for anticoagulation during PCI, including in HIT patients.
- What is Orforglipron used for?
- Oral GLP-1.
- Can you take Bivalirudin and Orforglipron together?
- Some users combine peptides within a single protocol, but stacking Bivalirudin and Orforglipron has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Bivalirudin or Orforglipron FDA-approved?
- Bivalirudin is FDA-approved for one or more indications. Orforglipron is FDA-approved for one or more indications.
Read the full articles
- Bivalirudin — full monograph: mechanism, research, dosing & references
- Orforglipron — full monograph: mechanism, research, dosing & references